These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2148990)

  • 21. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors.
    Penglis PS; Cleland LG; Demasi M; Caughey GE; James MJ
    J Immunol; 2000 Aug; 165(3):1605-11. PubMed ID: 10903770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
    Bhagwat SS; Gude C; Cohen DS; Lee W; Furness P; Clarke FH
    J Med Chem; 1991 Jun; 34(6):1790-7. PubMed ID: 1829485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 1.
    Ohshima E; Takami H; Sato H; Obase H; Miki I; Ishii A; Karasawa A; Kubo K
    J Med Chem; 1992 Sep; 35(18):3394-402. PubMed ID: 1388207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.
    Patscheke H
    Blut; 1990 May; 60(5):261-8. PubMed ID: 2190651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of thromboxane A2 inhibition and antagonism on prostaglandin and leukotriene synthesis in glomerular immune injury.
    Lianos EA; Bresnahan BA
    J Lab Clin Med; 1999 Nov; 134(5):478-82. PubMed ID: 10560941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thromboxane A2 and related prostaglandins in airways.
    Devillier P; Bessard G
    Fundam Clin Pharmacol; 1997; 11(1):2-18. PubMed ID: 9182072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
    Johnson GJ; Dunlop PC; Leis LA; From AH
    Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiological actions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191.
    Humphrey PP; Hallet P; Hornby EJ; Wallis CJ; Collington EW; Lumley P
    Circulation; 1990 Jan; 81(1 Suppl):I42-52; discussion I59-60. PubMed ID: 2136817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New trends in thromboxane and prostacyclin modulators.
    Dogné JM; de Leval X; Delarge J; David JL; Masereel B
    Curr Med Chem; 2000 Jun; 7(6):609-28. PubMed ID: 10702629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The biological role of thromboxane A2 in the process of hemostasis and thrombosis; pharmacology and perspectives of therapeutical use of thromboxane synthetase inhibitors and receptor PGH2/TXA2 antagonists.
    Radomski M
    Acta Physiol Pol; 1985; 36(3):153-64. PubMed ID: 3915630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
    Vezza R; Mezzasoma AM; Venditti G; Gresele P
    Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention.
    Nicosia S; Patrono C
    FASEB J; 1989 Jun; 3(8):1941-8. PubMed ID: 2542112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.